Crossmark

ASO Visual Abstract: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score—A Multicenter Study

Crossref DOI link: https://doi.org/10.1245/s10434-024-16313-6

Published Online: 2024-10-04

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakazawa, Nobuhiro

Sohda, Makoto

Hosoi, Nobuhiro

Watanabe, Takayoshi

Kumakura, Yuji

Yamashita, Toshiki

Tanaka, Naritaka

Saito, Kana

Kimura, Akiharu

Kasuga, Kengo

Nakazato, Kenji

Yoshinari, Daisuke

Shimizu, Hisashi

Ubukata, Yasunari

Hosaka, Hisashi

Sano, Akihiko

Sakai, Makoto

Ogawa, Hiroomi

Shirabe, Ken

Saeki, Hiroshi
License Information

Text and Data Mining valid from 2024-10-04

Version of Record valid from 2024-10-04
More Information

Article History

First Online: 4 October 2024

Disclosure

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below